The Effect of Sevoflurane on Airway Hyperreactivity During the Perioperative Period.

An Observational Study on the Effect of Sevoflurane on Airway Hyperreactivity in Children with RSV Infection During the Perioperative Period.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06694675

Enrollment

Registered

2024-11-19

Start date

2022-02-01

Completion date

2024-01-31

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia, RSV Infection in Children Less Than 5 Years of Age

Keywords

Sevoflurane, general anesthesia, RSV infection, pediatric patients

Brief summary

To investigate the effects of sevoflurane on respiratory parameters and respiratory inflammation in healthy and RSV-infected under general anesthesia and to propose suitable perioperative airway protection measures for children with respiratory virus infection undergoing general anesthesia.

Interventions

DRUGSevoflurane (Volatile Anesthetic)

Sevoflurane 1%\ 3.5%

DRUGpropofol

Propofol 9\ 15mg/kg/h

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

2 Years to 5 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients voluntarily joined this study and signed an informed consent form； 2. Age: 2-5 years old； 3. The patient should have a good general condition and no serious internal medicine comorbidities (ASA classification of the American Anesthesiology Association is Grade I); BMI ≤ 20; 4. Plan to undergo elective adenoidectomy or adenotonsillectomy with tracheal intubation.

Exclusion criteria

1. Children with a history of allergic asthma; 2. Children with space-occupying lesions of the chest and lungs, or acute bronchiolitis or pneumonia; 3. Children with cardiovascular diseases that may cause cough, wheezing, and other symptoms; 4. Children who used leukotriene modulators, β2 receptor agonists, anticholinergics, theophyllines, or hormonal treatment drugs within two weeks; 5. Children allergic to propofol, sevoflurane, or other anesthetic agents; 6. Children with a family history of malignant hyperthermia; 7. Children with liver and kidney dysfunction; 8. The result of rapid antigen detection and nucleic acid test for RSV was inconsistent, or children combined with pathogen infections other than RSV; 9. Children with fever.

Design outcomes

Primary

Measure	Time frame	Description
Intraoperative ventilator parameters	After induction of general anesthesia and intubation; at the end of anesthesia	Airway pressure(including Paw, PIP, Pplat), and pulmonary compliance.

Secondary

Measure	Time frame	Description
Inflammation response indications	After induction of general anesthesia and intubation; at the end of anesthesia	The level of NLRP3 and IL-1β measured by ELISA in the tracheal secretions of the patients

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026